News
-
Ampio Announces Positive Preliminary Update On The Optina™ Clinical Trial To Treat Diabetic Macular Edema And Decision To Conclude The Study Ahead Of Schedule
3/20/2012
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane™ completed two phase III studies, Ampion™-completed proof of concept studies and Optina™), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina™ trial for diabetic macular edema.
-
Ampio Pharmaceuticals, Inc. Announces Statistically Significant Improvement In Pain Relief For Its Lead Product, Ampion In The Osteoarthritis Of The Knee Trial
2/1/2012
Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced preliminary results of the pain score portion of the expansion phase of Ampion™ in Knee (AIK) trial which was recently completed in Australia.
-
BrainStorm Announces Clinical Data For Safety And Supporting Efficacy Of NurOwn™ Based On Initial Phase I/II Results
1/18/2012
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, recently announced that the data from the initial patients in its ALS Phase I/II human clinical trial treated with its NurOwn™ technology did not present any significant side effects and that the NurOwn™ treatment has so far proven to be safe.
-
Hospira Announces Start Of U.S. Phase III Biosimilar EPO Clinical Program
1/10/2012
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced enrollment of the first patient in a Phase III U.S. clinical program for its biosimilar erythropoietin (EPO).
-
Sangamo BioSciences Announces Initiation Of Two New Phase 2 HIV Clinical Trials
1/10/2012
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS.
-
Achillion Reports Clinical Data On Portfolio Of Protease Inhibitors
1/10/2012
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported new clinical trial results on its portfolio of protease inhibitors including: Phase 2 interim 12-week treatment results with ACH-1625 for the treatment of genotype 1 treatment-naive hepatitis C virus (HCV), exploratory data on ACH-1625 for the treatment of HCV genotype 3, and initial proof-of-concept data for ACH-2684.
-
BioMarin Announces IND For BMN-111 For Achondroplasia Is Active
1/4/2012
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is active. The company expects to initiate the Phase 1 trial in the first quarter of 2012.
-
Neuralstem's NSI-189 Trial In Major Depressive Disorder Receives FDA Approval To Advance To Phase Ib
12/27/2011
Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical trial to test its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder (MDD).
-
Isis Adds Three New Drugs To Its Development Pipeline
12/16/2011
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has added three new drugs to its development pipeline, ISIS-APOARx, ISIS-DGAT2Rx and ISIS-FVIIRx.
-
Simcere And Bristol-Myers Squibb Enter Innovative Partnership To Develop Cardiovascular Compound
12/15/2011
Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today announced that the companies have expanded the strategic partnership formed last year to include a second collaboration in a different therapeutic area.
This website uses cookies to ensure you get the best experience on our website. Learn more